Phyllis† and Veronica† are both:
- Postmenopausal women
- Hormone receptor (HR)-positive
- Human epidermal growth factor receptor 2 (HER2)-negative
- Patients with advanced breast cancer (ABC) whose disease has progressed on or after endocrine therapy
Phyllis shares some characteristics with patients in the PALOMA-3‡ Trial1
- Disease progressed after aromatase inhibitor (AI) therapy
- Bone-only metastases
The PALOMA-3 Trial studied FASLODEX + palbociclib. FASLODEX may be right for your patients like Phyllis.
*In combination with palbociclib or abemaciclib.
†Individual results may vary. This is not a real patient. This representation was not designed to reflect efficacy for an individual patient subgroup.
‡PALOMA-3 was a phase 3, international, randomized, double-blind, parallel-group, multicenter study of FASLODEX 500 mg in combination with palbociclib 125 mg vs FASLODEX plus placebo in 521 women with HR-positive, HER2-negative ABC whose disease progressed on or after prior endocrine therapy.1,3
§MONARCH 2 was a phase 3, randomized, double-blind, placebo-controlled, multicenter, international study of FASLODEX 500 mg in combination with abemaciclib 150 mg vs FASLODEX plus placebo in 669 women with HR-positive, HER2-negative ABC or metastatic breast cancer (mBC) that progressed while receiving prior endocrine therapy in the neoadjuvant, adjuvant, or early-line metastatic setting.1,2
References: 1. FASLODEX® (fulvestrant) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018. 2. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-439. 3. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875-2884.